Study Shows Two-Year Clinical Benefits for Kidney Disease Risk Test
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
The approval allows Quest Diagnostics to offer its minimal residual disease test for patients in all 50 states.
With the first FDA-cleared test and clinical guidelines debuting since May 2025, labs are evaluating how blood-based biomarkers fit into diagnostic protocols.
The company’s product, Slideflow Pro, is a scalable and modular platform designed to analyze digitized pathology slides and support the development of AI-based biomarkers that can help answer clinically important questions in cancer care.
The Fleming Initiative and Cepheid have launched a 30-month study in England to compare rapid molecular and traditional culture screening for drug-resistant carbapenemase-producing Enterobacterales in hospital settings.
A simplified test of HDL's ability to remove cholesterol was associated with high-risk coronary plaques in a study of 61 patients.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
Research suggests that only 12% of men receiving testosterone prescriptions underwent appropriate testing.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.